Silica – a nanomaterial?
Notification of a cosmetic product containing nano-form ingredients can be complex and involves more costs for the company (cosmetic product owner). The best way to simplify the notification process is to make sure that the Silica and related ingredients used do not fall to the nanomaterial category.

Silica, also known as silicone dioxide, is a mineral composed of silicon and oxygen and is used in cosmetics and personal care products, especially in make-up products. The type of Silica used in these products is the amorphous silica, which means it does not have a specific arrangement of the atoms and consequently it does not have a definite form. Silica (amorphous form) is also used as a food additive in the European Union (EU) and United States (U.S. approved by the Food and Drug Administration (FDA)). Silica related products, such as hydrated silica, alumina magnesium metasilicate, aluminium calcium sodium silicate, aluminium iron silicates and sodium potassium aluminium silicate, are also used as cosmetic ingredients in the EU.

According to the European Cosmetic Regulation No. 1223/2009, a ‘nanomaterial’ is described as “an insoluble or biopersistant and intentionally manufactured material with one or more external dimensions, or an internal structure, on the scale from 1 to 100 nm”. Cosmetic products containing ‘nanomaterials’ are subject to a specific notification to the European Commission and the Responsible Person must notify “it by electronic means six months prior to being placed on the market”.

The European Commission’s Scientific Committee on Consumer Safety (SCCS) has issued an opinion regarding Silica (Synthetic Amorphous Silica – SAS) and its solubility and consequent classification as a nanomaterial. The SCCS stated that “In regard to the nanomaterial definition in the Cosmetic Regulation, none of the SAS materials (hydrophilic or hydrophobic) included in the dossier can be regarded as soluble”. It means that the SCCS considered that Silica is insoluble and, if more than 50% of its particles has a size below 100 nanometers, it may classify as a nanomaterial. This opinion applies to Silica and related materials (Hydrated Silica, Silica Dimethyl Silylate, Silica Silylate, Silica Dimethicone Silylate, Silica Caprylyl Silylate and, Silica Cetyl Silylate).

The Association of Synthetic Amorphous Silica Producers (ASASP) is composed by 9 members that represent the majority of synthetic amorphous silica (SAS) producers in Europe and considers that SAS is soluble and should not be regarded as a nanomaterial.

Nevertheless, the suppliers of raw materials containing Silica must provide documentation regarding the particle size distribution in the ingredient to confirm if the particle size is below the cut-off limit and if it consequently needs to be regarded as the nano-form (according to SCCS opinion).

If a cosmetic product contains Silica in the nano-form (or other ingredient in this form), it must be clearly indicated in the list of ingredients in the product label. The name of the ingredient shall be followed by the word ‘nano’ in brackets (e.g. Silica [NANO]).

The SCCS has published a scientific advice on the safety of nanomaterials in cosmetics. The Committee has identified some aspects of nanomaterials that constitute a basis for concern over safety to consumers’ health when used in cosmetics, including physicochemical aspects (e.g. very small dimensions of particles), exposure aspects (e.g. frequency and amounts applied, potential for systemic exposure and accumulation in the body) and other aspects (like novel properties). These concerns where detailed in the document in three separate annexes.

With the development of scientific knowledge and continuous investigation, nanomaterials are being used in cosmetics more and more. Nevertheless, caution must be taken since there are certain aspects of these ingredients that are not yet fully known and may represent a safety concern.

References:

  1. European Food Safety Authority – Re-evaluation of Silicon Dioxide (E 551) as a food additive. Available at: https://efsa.onlinelibrary.wiley.com/doi/10.2903/j.efsa.2018.5088
  2. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. Available at: https://ec.europa.eu/health/sites/health/files/endocrine_disruptors/docs/cosmetic_1223_2009_regulation_en.pdf
  3. Scientific Committee on Consumer Safety (SCCS). Opinion on solubility of Synthetic Amorphous Silica (SAS). SCCS/1606/19. Available at: https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_228.pdf
  4. Synthetic Amorphous Silica (SAS) industry response to the opinion of the Scientific Committee on Consumer Safety (SCCS) on silica in cosmetics with regard to solubility. Available at: https://www.asasp.eu/images/Publications/ASASP1101b_-_ASASP_response_to_solubility_SCCS_Opinion_Dec_2019_final.pdf
  5. Scientific Committee on Consumer Safety (SCCS). Scientific Advice on the safety of nanomaterials in cosmetics (SCCS/1618/20). Available at: https://ec.europa.eu/health/sites/health/files/scientific_committees/consumer_safety/docs/sccs_o_239.pdf

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »